Subtyping of Group 3/4 medulloblastoma as a potential prognostic biomarker among patients treated with reduced dose of craniospinal irradiation: a Japanese Pediatric Molecular Neuro-Oncology Group study

BACKGROUND: One of the most significant challenges in patients with medulloblastoma is reducing the dose of craniospinal irradiation (CSI) to minimize neurological sequelae in survivors. Molecular characterization of patients receiving lower than standard dose of CSI therapy is important to facilita...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukuoka, Kohei, Kurihara, Jun, Shofuda, Tomoko, Kagawa, Naoki, Yamasaki, Kai, Ando, Ryo, Ishida, Joji, Kanamori, Masayuki, Kawamura, Atsufumi, Park, Young-Soo, Kiyotani, Chikako, Akai, Takuya, Keino, Dai, Miyairi, Yosuke, Sasaki, Atsushi, Hirato, Junko, Inoue, Takeshi, Nakazawa, Atsuko, Koh, Katsuyoshi, Nishikawa, Ryo, Date, Isao, Nagane, Motoo, Ichimura, Koichi, Kanemura, Yonehiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10521425/
https://www.ncbi.nlm.nih.gov/pubmed/37749662
http://dx.doi.org/10.1186/s40478-023-01652-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10521425/
https://www.ncbi.nlm.nih.gov/pubmed/37749662
http://dx.doi.org/10.1186/s40478-023-01652-4

Ejemplares similares